【财华社讯】东阳光药(06887.HK)公布，董事会接获公司控股股东集团成员张寓帅及郭梅兰告知，鉴于 郭梅兰决定退休并减少参与集团业务，于2025年12月29日，张寓帅与郭梅兰订立股权转让协议，据此郭 梅兰将其分别于乳源寓能电子及乳源新京科技持有的71.75%股权及74.63%股权转让张寓帅，转让之名 义代价各分别为人民币1.00元。郭梅兰为张寓帅的母亲。 完成相关监管备案及股权转让交割后，张寓帅将分别持有乳源寓能电子及乳源新京科技99.2%及75.0% 股权，从而成为控股股东集团的新领导人，而郭梅兰将不再为控股股东集团成员。 董事认为，股权转让对公司整体财务及营运不会产生任何不利影响。 本文源自：财华网 ...

董事认为，股权转让对本公司整体财务及营运不会产生任何不利影响。 智通财经APP讯，东阳光药(06887)发布公告，本公司董事会接获张寓帅先生(张先生)及郭梅兰女士(郭女 士)(各自作为本公司的控股股东集团成员)(控股股东)告知，鉴于郭女士决定退休并减少参与本集团业 务，于2025年12月29日，张先生与郭女士订立股权转让协议，郭女士将其分别于乳源瑶族自治县寓能电 子实业有限公司(乳源寓能电子)及乳源瑶族自治县新京科技发展有限公司(乳源新京科技)持有的71.75% 股权及74.63%股权转让张先生，转让的名义代价各分别为人民币1.00元(股权转让)。郭女士为张先生的 母亲。 完成相关监管备案及股权转让交割后，张先生将分别持有乳源寓能电子及乳源新京科技99.2%及75.0% 股权，从而成为控股股东集团的新领导人，而郭女士将不再为控股股东集团成员。 ...

董事认为，股权转让对本公司整体财务及营运不会产生任何不利影响。 完成相关监管备案及股权转让交割后，张先生将分别持有乳源寓能电子及乳源新京科技99.2%及75.0% 股权，从而成为控股股东集团的新领导人，而郭女士将不再为控股股东集团成员。 东阳光（600673）药(06887)发布公告，本公司董事会接获张寓帅先生(张先生)及郭梅兰女士(郭女士)(各 自作为本公司的控股股东集团成员)(控股股东)告知，鉴于郭女士决定退休并减少参与本集团业务，于 2025年12月29日，张先生与郭女士订立股权转让协议，郭女士将其分别于乳源瑶族自治县寓能电子实业 有限公司(乳源寓能电子)及乳源瑶族自治县新京科技发展有限公司(乳源新京科技)持有的71.75%股权及 74.63%股权转让张先生，转让的名义代价各分别为人民币1.00元(股权转让)。郭女士为张先生的母亲。 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） 內幕消息 控股股東集團成員間的股權轉讓 本 公 告 乃 由 廣 東 東 陽 光 藥 業 股 份 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱 「本集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及 香港法例第571章證券及期貨條例第XIVA部下的內幕消息條文（ 定義見上市規則 ） 而作出。 股權轉讓 本公司董事（「董事」）會（「董事會」）接獲張寓帥先生（「張先生」）及郭梅蘭女士（「郭 女士」）（ 各自作為本公司之控股股東集團成員（ 定義見上市規則 ））（「控股股東」）告 知 ， 鑒 於 郭 女 士 決 定 ...

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) is a leading company in the influenza sector with a solid foundation and a rich pipeline of innovative products, focusing on three main areas: anti-infection, chronic diseases, and oncology. The company maintains a leading position in the anti-infection field, particularly in influenza, hepatitis C, and hepatitis B, and has been given a "Buy" rating by Huafu Securities [1]. Group 1: Anti-Infection - The company holds a leading position in the influenza market, with Oseltamivir ranking first in domestic market share and possessing the largest production base globally, ensuring sufficient supply capacity [2]. - The hepatitis C pipeline includes the approval of pan-genotypic therapies, with NMPA approvals for Phosphoribosyl-1-pyrophosphate and Acalabrutinib expected in February and March 2025, respectively [2]. - For hepatitis B, the fastest progress is seen with Mofetil, which is the only product in China entering Phase III clinical trials, while the siRNA therapy (HECN30227) is set to enter clinical stages in October 2025 [2]. Group 2: Chronic Diseases - Ifenprodil is identified as a potential blockbuster drug (BIC) targeting the $4 billion global market for idiopathic pulmonary fibrosis, with Phase I trials completed in China and the US, and promising Phase II data showing a 96% delay in decline compared to placebo [3]. - Insulin products are nearing FDA approval, with Glargine expected to receive BLA approval in the first half of 2026, while Aspart has a Pre-IND application submitted, with plans to file for BLA by the end of 2025 and anticipate approval by the end of 2026 [3]. Group 3: Oncology - The company expects the approval of Clifosfamide for acute myeloid leukemia (AML) by 2027, having formed a partnership with 3SBio for this product [4]. - The oncology pipeline is rich, including Lenvatinib (Phase III) for esophageal cancer, HEC53856 (Phase II) for chemotherapy-induced anemia, and HEC201625 (upcoming IND) as an oral PD-L1 small molecule, with ongoing efforts in new technology areas such as ADC and TCE [4]. Group 4: Profit Forecast - The company is projected to achieve net profits attributable to shareholders of 250 million, 540 million, and 930 million yuan for the years 2025, 2026, and 2027, respectively, with price-to-sales ratios of 4.5, 3.7, and 3.2 times, indicating a strong value proposition compared to peers [5].

Core Viewpoint - Dongyang Sunshine Pharmaceutical has been awarded the "Annual Outstanding Biopharmaceutical Enterprise" at the "Technology Empowerment · Capital Breakthrough" sharing session, highlighting its achievements in innovation and research in the biopharmaceutical sector [1][3]. Company Overview - Dongyang Sunshine Pharmaceutical (06887.HK) is engaged in drug research, production, and commercialization, focusing on innovative drugs, including modified new drugs, generics, and biosimilars. The company emphasizes innovation, internationalization, and sustainability, driven by independent research and development [3]. - The company has established a comprehensive R&D system over 20 years, employing over 1,100 R&D personnel, including more than 20 foreign and returned experts. It has received the Guangdong Province Innovation Team title six times and holds over 2,500 patents [3][4]. Strategic Focus - The company adheres to "independent innovation" as its core strategy, deepening its "internationalization" efforts while focusing on three key therapeutic areas: infections, chronic diseases, and tumors. It employs diverse technologies, including small molecules, antibodies, small nucleic acids, ADC, and cell therapies [4]. - Dongyang Sunshine has launched three original innovative drugs and has 49 first-class innovative drugs in development, with one nearing market launch and ten in clinical phases II and III. Several pipeline products have "First in class" or "Best in class" potential [4]. Recent Achievements - In 2024, two candidate drugs are expected to achieve external cooperation and licensing agreements, with a total transaction value exceeding $1 billion [4]. - The company is addressing the global challenge of functional cure for hepatitis B with its small nucleic acid drugs and has the only complete independent intellectual property treatment plan for pan-genotype hepatitis C in China [4]. - Dongyang Sunshine's insulin product, Glargine, is set to be approved for sale in the U.S., making it the first Chinese company to market insulin in the U.S. Additionally, its new diabetes drug, Ologliptin, is also nearing approval [4].

Core Insights - The "Annual Outstanding Biopharmaceutical Enterprises" award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications [4] Group 1: Award Announcement - The "Annual Outstanding Biopharmaceutical Enterprises" award was announced during the "Technology Empowerment, Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1] - Eight companies were awarded, including Baillie Tianheng (688506.SH), Dongyang Sunshine Pharmaceutical (06887.HK), Dongyao Pharmaceutical-B (01875.HK), and others, listed in alphabetical order [1] Group 2: Evaluation Criteria - The evaluation for the award was based on a comprehensive assessment of technical innovation, research and development strength, and achievement transformation [4] - The final results were derived through quantitative data analysis and expert review [4] Group 3: Purpose of the Award - Gelonghui aims to create a reference value ranking for listed companies and unicorns in the investment community with the "Golden Gelong Award" [4] - The award covers all listed companies and unicorns on major exchanges including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4]

Core Insights - The "Annual Outstanding Biopharmaceutical Enterprises" award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications [4] Group 1: Award Announcement - The "Annual Outstanding Biopharmaceutical Enterprises" award will be announced during the "Technology Empowerment, Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1] - Eight companies, including Baillie Gifford (688506.SH), Dongyang Sunshine Pharmaceutical (06887.HK), Dongyao Pharmaceutical-B (01875.HK), and others, have been awarded the title [1] Group 2: Evaluation Criteria - The evaluation for the award is based on a comprehensive assessment of technical innovation, research and development strength, and achievement transformation [4] - The final results were determined through quantitative data analysis and an expert review panel [4] Group 3: Purpose of the Award - Gelonghui aims to create a reference value ranking for listed companies and unicorns in the investment community with the "Golden Gelong Award" [4] - The award covers all listed companies and unicorns on major exchanges, including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4]

廣東東陽光藥業股份有限公司 章程 經二零二五年十二月十六日之臨時股東大會審議、修訂並通過 並於二零二五年十二月十六日生效 | 第⼀章 | 總則 | 3 | | --- | --- | --- | | 第二章 | 公司的經營宗旨和範圍 | 5 | | 第三章 | 股份 | 6 | | 第⼀節 | 股份發行 | 6 | | 第二節 | 股份增減和回購 | 11 | | 第三節 | 股份轉讓 | 12 | | 第四章 | 股東和股東大會 | 13 | | 第⼀節 | 股東 | 13 | | 第二節 | 股東大會的⼀般規定 | 16 | | 第三節 | 股東大會的召集 | 18 | | 第四節 | 股東大會的提案與通知 | 20 | | 第五節 | 股東大會的召開 | 21 | | 第六節 | 股東大會的表決和決議 | 25 | | 第五章 | 董事會 | 27 | | 第⼀節 | 董事 | 27 | | 第二節 | 董事會 | 30 | | 第三節 | 董事會專門委員會 | 35 | | 第六章 | 高級管理人員 | 35 | | 第七章 | 監事會 | 38 | | 第⼀節 | 監事 | 38 | | 第二節 | ...

（股份代號：6887） 2025年第二次臨時股東大會投票表決結果 茲 提 述 廣 東 東 陽 光 藥 業 股 份 有 限 公 司（「 本 公 司 」）日 期 為 2025 年 11 月 28 日 的 通 函 （「通函」）。除文義另有所指外，本公告所用詞彙與通函所界定者具相同涵義。 臨時股東大會投票表決結果 臨時股東大會已於2025年12月16日（ 星期二 ）假座中國廣東省東莞市長安鎮振安中 路 368 號 東 陽 光 科 技 園 銷 售 樓 三 樓 會 議 室 召 開 及 舉 行 。 臨 時 股 東 大 會 乃 依 照 公 司 法及其他相關中國法律法規、香港上市規則以及公司章程的規定合法而有效地召 開。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊 ...